---------------------------------
OMB APPROVAL
---------------------------------
---------------------------------
OMB Number: 3235-0167
Expires: November 30, 2010
Estimated average burden
hours per response........1.50
---------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1 on
FORM 15/A
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-10581
Bentley Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Bentley Park, 2 Holland Way, Exeter, NH 03833, (603) 658-6100
--------------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
Common Stock, par value $0.02 per share
Series A Junior Participating Preferred
Stock purchase rights
--------------------------------------------------------------------------------
(Title of each class of securities covered by this Form)
None
--------------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) [X]
Rule 12g-4(a)(2) [ ]
Rule 12h-3(b)(1)(i) [X]
Rule 12h-3(b)(1)(ii) [ ]
Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or
notice date: 1
Explanatory Note: The purpose of this Amendment No. 1 on Form 15/A is to
withdraw the previous filing of this Form 15 with respect to
to the securities covered by this Form and to replace such
filing with this Amendment No. 1 on Form 15/A.
Pursuant to the requirements of the Securities Exchange Act of 1934,
Bentley Pharmaceuticals, Inc. has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
Date: July 23, 2008 By: /s/ Brian E. Shanahan
-----------------------------------------
Name: Brian E. Shanahan
Title: Assistant Secretary
Persons who respond to the collection of information
contained in this form are not required to respond unless
SEC 2069 (02-08) the form displays a currently valid OMB control number.